Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction  by Waters, Richard E et al.
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The focus for the initial approach to the treatment of acute ST-segment elevation myocardial
infarction (STEMI) has shifted toward extending the benefits of mechanical reperfusion with
primary percutaneous coronary intervention (PCI) to patients who present to community
hospitals that have no interventional capabilities. Several randomized clinical trials have
shown that transferring STEMI patients to tertiary centers for primary PCI leads to better
outcomes than when fibrinolytic therapy is administered at community hospitals. Further-
more, potent pharmacologic reperfusion regimens that enhance early reperfusion of the
infarct vessel before primary PCI may enhance the positive result of the transfer approach.
Despite these promising findings, several obstacles have hindered the adoption of patient-
transfer strategies in the U.S., including greater distances between community and tertiary
hospitals, a lack of integrated emergency medical services, and the medical community’s
limited experience with centralized acute myocardial infarction (AMI) care networks.
Nonetheless, the implementation of system-wide changes in the care of STEMI patients
analogous to the creation of trauma networks could facilitate the creation and ongoing
evaluation of dedicated patient transfer strategies and better early invasive care in the U.S.
Within this context, a systematic, stepwise approach to the creation of AMI care networks
and to the development of standard nomenclature and performance indicators is necessary to
guide quality assurance monitoring and future research efforts as the care of STEMI patients
is redefined. Consequently, this current evolution of reperfusion strategies has the potential
to further reduce morbidity and mortality for patients presenting with STEMI. (J Am Coll
Cardiol 2004;43:2153–9) © 2004 by the American College of Cardiology Foundationp
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mreatment strategies for acute ST-segment elevation myo-
ardial infarction (STEMI) have evolved dramatically over
he last two decades. Acute coronary reperfusion is accom-
lished pharmacologically with fibrinolytic therapy or me-
hanically with primary percutaneous coronary intervention
PCI). Primary PCI provides more effective and sustained
arly reperfusion than fibrinolytic therapy, but it is available
n only a minority of hospitals in the U.S. (1,2).
A similar predicament with emergency trauma care in the
.S. has led to the successful formation of regional trauma
etworks in which trauma patients are preferentially trans-
orted to and treated by experienced trauma centers (2).
ith the publication of studies documenting improvement
n clinical outcomes with regional trauma networks, the
umber of U.S. trauma centers has increased (3,4). There-
ore, we propose that an analogous treatment network for
atients with STEMI be developed to offer the benefits of
From Duke University Medical Center and Duke Clinical Research Institute,
urham, North Carolina.
Manuscript received October 27, 2003; revised manuscript received December 19,c003, accepted December 23, 2003.rimary PCI to larger segments of the U.S. population. We
xamine the rationale for adopting transfer protocols for
rimary PCI, explore the options of coupling pharmacologic
nd mechanical reperfusion therapies, and delineate steps
ecessary to implement and study STEMI transfer strate-
ies and networks.
ENEFITS OF PRIMARY PCI
rimary PCI has emerged as the preferred reperfusion
trategy for patients with STEMI at institutions with
ppropriate interventional capabilities and experience.
hen accomplished quickly by skilled operators, primary
CI leads to decreased rates of mortality, reinfarction,
troke, and hemorrhagic complications compared with full-
ose fibrinolysis (1). In a recent systematic overview of data
rom 11 fibrinolysis versus primary PCI trials, patients in
he primary PCI arm had lower rates of mortality, nonfatal
einfarction, and stroke compared with patients given full-
ose fibrinolytic therapy (Fig. 1) (1). The results of another
eta-analysis comparing 23 fibrinolysis versus primary PCIomparison trials for STEMI revealed similar findings (5).
A
p
l
t
G
T
T
p
i
h
p
1
p
c
p
i
t
P
N
a
p
p
i
c
R
w
h
w
t
r
f
(
r
m
1
f
e
F
(

2154 Waters et al. JACC Vol. 43, No. 12, 2004
Establishing Transfer Protocols for STEMI Patients June 16, 2004:2153–9lthough these overviews likely overestimate the benefit of
rimary PCI in “real-world” clinical practice, they neverthe-
ess provide strong evidence that mechanical reperfusion is
he preferred therapeutic approach for STEMI.
EOGRAPHIC DISPARITIES IN
HE AVAILABILITY OF PRIMARY PCI
he widespread use of primary PCI is restricted by a lack of
roperly equipped hospitals and experienced staff. Cluster-
ng of interventional hospitals in cities and suburban areas
as left vast regions of the U.S. without timely access to
Abbreviations and Acronyms
AMI  acute myocardial infarction
AIR-PAMI  Air Primary Angioplasty in Myocardial
Infarction
DANAMI  Danish Multicenter Randomized Trial on
Thrombolytic Therapy Versus Acute
Coronary Angioplasty in Acute
Myocardial Infarction
MI  myocardial infarction
PCI  percutaneous coronary intervention
PRAGUE  Primary Angioplasty After Transport of
Patients from General Community
Hospitals to Catheterization Units With/
Without Emergency Thrombolysis
Infusion
SK  streptokinase
STEMI  ST-segment elevation myocardial
infarction
igure 1. Mortality to 30 days for ST-segment elevation myocardial infarcti
PTCA) versus fibrinolytic therapy (lytic). Reproduced with permission froconfidence interval; SK  streptokinase; tPA  tissue plasminogen activatorrimary PCI. In a recent STEMI registry, only 39% of the
,506 participating U.S. hospitals had the recommended
rimary PCI capabilities with back-up cardiac surgical
overage (6,7). Accurate and comprehensive data for all
rimary PCI-capable hospitals in the U.S. do not exist, but
t is likely that most primary PCI centers are in moderate-
o large-size communities with greater populations.
RIMARY PCI AT COMMUNITY HOSPITALS
ew treatment strategies and changes in health care systems
re needed to extend the benefits of primary PCI to more
atients with STEMI. One approach is to offer onsite
rimary PCI in community hospitals with cardiac catheter-
zation laboratories but without cardiac surgical back-up
overage. The Atlantic Cardiovascular Patient Outcomes
esearch Team examined the feasibility of this approach
hen they introduced primary PCI at 11 community
ospitals equipped with catheterization laboratories but
ithout PCI or cardiac surgery programs (8). After initial
raining in performing PCI, doctors at participating sites
andomly assigned STEMI patients to primary PCI or
ull-dose fibrinolysis. Despite early termination of this study
funding limitations and poor enrollment), the incidence of
ecurrent myocardial infarction (MI), stroke, or death at six
onths was reduced in the primary PCI arm (12.4% vs.
9.9%; p  0.03). However, these findings were con-
ounded by insufficient power to show definitive results and
arly study termination.
Further studies evaluating primary PCI in community
tients treated with primary percutaneous transluminal coronary angioplasty
e Primary Coronary Angioplasty Trialists’ (PCAT) Collaborators (1). CIon pa
m th.
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June 16, 2004:2153–9 Establishing Transfer Protocols for STEMI Patientsospitals are needed to determine the efficacy or feasibility
f implementing such a strategy. Additionally, the financial
nd institutional commitment required to create a primary
CI program in a hospital that has only a diagnostic
atheterization laboratory needs to be more fully defined.
urrent guidelines recommend that when no on-site sur-
ery program exists, primary PCI should be performed only
t institutions with a proven plan for rapid access (within
0 min) to a nearby facility with capability for performing at
east 36 primary PCI procedures per year by skilled opera-
ors (who perform at least 75 PCI procedures per year) (7).
iven these limitations, a strategy for the interhospital
ransfer of STEMI patients from community hospitals to
ertiary hospitals equipped to perform primary PCI may be
ore feasible and may capitalize on the resources already
resent at tertiary hospitals.
RANSFER FOR PRIMARY PCI
n the largest experience of transfer for primary PCI, the
anish Multicenter Randomized Trial on Thrombolytic
herapy Versus Acute Coronary Angioplasty in Acute
yocardial Infarction (DANAMI-2), 1,572 patients with
TEMI were randomly assigned to on-site accelerated
issue plasminogen activator or primary PCI at 24 hospitals
n Denmark (9). Patients who were randomized to primary
CI at referral centers were transferred to one of five
nvasive centers, provided that transfer would likely take
3 h. Transfer for primary PCI was well tolerated, with no
eaths or serious adverse events. The median transfer
istance was 50 km (range, 3 to 150 km), and the median
ransfer time was 67 min (interquartile range, 50 to 85 min).
he DANAMI-2 trial was stopped early because of an
pproximately 40% lower incidence of the primary end
oint of recurrent MI, disabling stroke, or death at 30 days
ith primary PCI compared with fibrinolysis (8.5% vs.
4.2%; p  0.002). However, the significance of these
ndings has been questioned because: 1) recurrent MI was
he only end point that was significantly reduced with
rimary PCI; 2) different definitions of MI were used in the
wo treatment groups; and 3) early-rescue PCI was prohib-
ted for reperfusion failures in the fibrinolytic group. None-
heless, the Danish experience reveals that a cohesive
etwork of centers could rapidly and safely transfer STEMI
atients for primary PCI.
In the Primary Angioplasty After Transport of Patients
rom General Community Hospitals to Catheterization
nits With/Without Emergency Thrombolysis Infusion
PRAGUE-1) study, the safety and feasibility of interhos-
ital transfer of patients with STEMI in the Czech
epublic was evaluated (10). Patients were randomly as-
igned to three groups: group A received intravenous strep-
okinase (SK); group B received SK with immediate transfer
o an invasive center for subsequent PCI; and group C was
ransported to an invasive center without receiving fibrino-
ytic therapy. Transfer was tolerated well, with rare nonfatal pomplications and no deaths. The primary composite end
oint (reinfarction, stroke, or death at 30 days) was reduced
cross groups A, B, and C (23%, 15%, and 8%, respectively;
 0.02).
The encouraging findings from the PRAGUE-1 trial
purred the subsequent nationwide PRAGUE-2 trial (11). In
RAGUE-2, 850 STEMI patients from community hospitals
n the Czech Republic were randomly assigned to on-site
brinolysis with SK or transfer to invasive centers for primary
CI. There was a modest trend toward reduction in the
rimary end point of 30-day mortality with primary PCI versus
K (6.8% vs. 10.0%; p  0.12). Analysis of a prespecified
ubgroup of patients who presented within 3 h of symptom
nset showed no mortality benefit with transfer for PCI (7.3%
s. 7.4%), whereas patients who presented within 3 to 12 h of
ymptom onset had a significant reduction in mortality (6.0%
s. 15.3%; p  0.02). Therefore, the PRAGUE-2 results
onfirm the feasibility of transferring STEMI patients for
rimary PCI but also suggest that transfer for primary PCI
ay primarily benefit patients who do not present soon after
ymptom onset.
The only clinical trial in the U.S. with transfer for
rimary PCI was the Air Primary Angioplasty in Myocar-
ial Infarction (AIR-PAMI) study, which included nine
.S. hospitals and three non-U.S. hospitals. High-risk
atients with STEMI who presented to community hospi-
als without interventional capabilities were assigned ran-
omly to fibrinolysis or immediate transfer to a nearby
ertiary center for primary PCI (12). The mean distance
etween community and invasive hospitals was 32 miles;
ean transport time was 33 min. After 39 months, the
IR-PAMI trial was terminated early because of slow
nrollment; only 138 patients (32% of the anticipated
ample size) were randomized. Despite early termination,
he study revealed that patients transferred for primary PCI
ad a nonsignificant lower risk of reinfarction, disabling
troke, or death at 30 days (8.4% vs. 13.6%; p  0.33). The
isappointing enrollment in the AIR-PAMI trial suggests
hat significant obstacles may impede studies of transferring
atients with STEMI for primary PCI in the U.S.
A recently published meta-analysis of results from fibri-
olysis versus primary PCI trials included data from five
rials (DANAMI-2, PRAGUE-1 and -2, AIR-PAMI, and
he Limburg Intervention/MI trial) that compared on-site
brinolysis with immediate transfer for primary PCI (5,13).
ombined data from these trials showed that transfer for
rimary PCI was associated with a significant decrease in
he composite end point of nonfatal MI, stoke, or death
ompared with fibrinolysis (Figs. 2 and 3). Two other
eviews had similar conclusions (14,15). These cumulative
esults underscore the concept that transferring STEMI
atients for primary PCI appears to be a superior reperfu-
ion strategy compared with on-site fibrinolysis at a com-
unity hospital, but time delays associated with transferringatients for PCI in routine clinical practice may be a major
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Establishing Transfer Protocols for STEMI Patients June 16, 2004:2153–9indrance to the more widespread adoption of transfer
trategies for community hospitals (2,6).
IME TO REPERFUSION WITH PRIMARY PCI
ata indicate that the earlier administration of fibrinolytics
fter the onset of symptoms improves myocardial salvage
nd preserves left ventricular function, resulting in a signif-
cant, time-dependent survival benefit (16). Although a
ime-to-treatment relation with primary PCI has not been
roven, a similar relation persists in data from observational
egistries. In data from more than 27,000 patients treated
ith primary PCI for STEMI in the National Registry of
yocardial Infarction-2, a direct relation was shown be-
ween shorter “door-to-balloon” times and lower adjusted
isks of mortality, although the time from onset of symp-
oms to balloon inflation actually showed little relation to
utcomes (17). Current guidelines for primary PCI recom-
end that balloon inflation be performed within 90 ( 30)
igure 2. Meta-analysis of short-term clinical outcomes in ST-segment
levation myocardial infarction patients treated with onsite fibrinolysis
ersus transfer for primary percutaneous transluminal coronary angioplasty
PTCA). Reproduced with permission from Keeley et al. (5).
igure 3. Mortality rates in clinical trials comparing onsite fibrinolysis
open bars) versus transfer for primary percutaneous coronary intervention
solid bars) for ST-segment elevation myocardial infarction. This figure is
ased on data presented by Keeley et al. (5). AIR-PAMI  Air Primary
ngioplasty in Myocardial Infarction trial (12); DANAMI  Danish
ulticenter Randomized Trial on Thrombolytic Therapy Versus Acute
oronary Angioplasty in Acute Myocardial Infarction trial (9); LIMI 
imburg Intervention/MI trial (13); PCI  percutaneous coronary inter-
ention; PRAGUE  Primary Angioplasty After Transport of Patients
rom General Community Hospitals to Catheterization Units With/tithout Emergency Thrombolysis Infusion Trials (10,11).in of hospital arrival (7,18). However, the average “door-
o-balloon” in the recent National Registry of Myocardial
nfarction-3 registry was slightly more than 2 h at primary
CI centers and more than 3 h for patients transferred from
community hospital to a tertiary hospital for primary PCI
6). Therefore, the administration of potent adjunctive
harmacologic agents at the time of initial presentation may
e synergistic and overcome the delays inherent in reperfu-
ion when transferring patients for primary PCI.
ERGING PHARMACOLOGIC
ND MECHANICAL REPERFUSION
mproved pharmacologic reperfusion regimens enhance
eperfusion before definitive mechanical recanalization and
ay be useful adjunctive therapies when combined with
transfer strategy for primary PCI (19 –23). The
RAGUE-1 trial included a “fibrinolysis-before-transfer”
rm, and a recent report from the largest PRAGUE-1
ontributing center (49% of total patients) described lower
ortality rates in this group of patients compared with both
fibrinolysis-only” and “transfer-only” patients (19). Because
imilar findings were not observed in the overall trial, these
esults should be interpreted cautiously; further studies are
nderway to investigate the potential benefits of full-dose
brinolysis before transfer for PCI. The administration of
he glycoprotein IIb/IIIa inhibitor abciximab before primary
CI improves reperfusion before PCI and has improved
linical outcomes in small studies and a systematic overview
20,21). An alternative approach that combines reduced-
ose fibrinolytic therapy  glycoprotein IIb/IIIa inhibitors
efore PCI also has shown favorable procedural and clinical
utcomes in small studies (22–24). Although these combi-
ations of adjunctive therapies before planned primary PCI
ust still be validated in large-scale randomized trials,
harmacologic reperfusion for patients initially presenting
o community hospitals may become the preferred initial
reatment strategy used before transferring patients to ter-
iary hospitals.
DOPTING TRANSFER STRATEGIES IN THE U.S.
ecause more than one-half of STEMI patients in the U.S.
resent to hospitals without on-site primary PCI and
ack-up coronary artery bypass grafting capabilities, the
pportunity exists for implementing a widespread transfer
trategy (6). However, in a recent study, patients transferred
or primary PCI between 6:00 PM and 8:00 AM had a greater
requency of failed PCI procedures; in another study,
rehospital fibrinolysis 2 h after symptom onset was
ssociated with improved survival compared with primary
CI, as in the PRAGUE-2 findings (11,25,26). Rapid risk
tratification protocols may help identify patients likely to
enefit from transfer for primary PCI compared with those
ho may benefit more from onsite fibrinolysis, for example,
atients who present early after the onset of symptoms or
hose not expected to receive significant benefit from pri-
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June 16, 2004:2153–9 Establishing Transfer Protocols for STEMI Patientsary PCI. Large-scale randomized studies are clearly
eeded to precisely define the “ideal” transfer population
nd delineate appropriate triage strategies.
To successfully implement transfer strategies for primary
CI in the U.S., obstacles must be overcome: delays due to
arge distances between hospitals in certain regions, highly
ariable skills and training of emergency medicine person-
el, and liability issues regarding complications that could
tem from the transfer. Additionally, current reimbursement
olicies for acute myocardial infarction (AMI) care may be
major deterrent to transferring patients for primary PCI;
uch patients represent potential financial losses to commu-
ity hospitals and financial gains for tertiary hospitals.
onetheless, transfer strategies could be implemented in the
.S. if the current structure of STEMI care were changed
2).
Integrated and coordinated acute STEMI systems similar
o trauma systems/networks should be established, with the
oals of improving the process of early care and the
utcomes of patients with STEMI (2). Acute STEMI
ystems could facilitate the immediate transfer of patients
ith STEMI to high-volume tertiary hospitals that have
rimary PCI capabilities because these hospitals have lower
ortality rates and improved procedural outcomes with
rimary PCI (27,28). However, the distribution of primary
CI-capable centers in the U.S. remains difficult to char-
cterize; therefore, accurate data regarding local population
ensities, distances between hospitals, and transportation
apabilities are needed before STEMI transfer networks can
e established. Nonetheless, we propose the following steps
o implement dedicated transfer strategies in local commu-
ities:
. The designation of centralized AMI centers located
within a reasonable distance from all referral community
hospitals; centers should have proven expertise in per-
forming primary PCI.
. The development of AMI teams at community hospitals
that can accurately identify STEMI patients eligible for
primary PCI, correctly administer preferred initial med-
ications, and rapidly transfer patients directly to the AMI
center.
. The central coordination and management of care at
community and tertiary hospitals.
. The implementation of quality monitoring to continually
assess processes of care and outcomes for patients trans-
ferred for primary PCI.
. The creation of clinical research networks to extend
AMI research into community hospitals and provide a
structure to prospectively evaluate transfer strategies and
adjunctive pharmacologic regimens.
NITIAL EXPERIENCES WITH TRANSFER
TRATEGIES FOR PRIMARY PCI IN THE U.S.
sing the steps described in the previous text, the Duke
niversity Medical Center has recently implemented a Segional transfer system for STEMI. Prompt transfer mech-
nisms have been developed with local emergency medical
ervices systems, and communications have been stream-
ined via a central network. Immediate transfer is stimulated
y a single telephone call from the referring hospital. All
easures of care and long-term outcomes are collected for
ngoing quality assurance monitoring. Although early in its
nception, this transfer strategy at Duke University Medical
enter has generated positive responses from all participat-
ng clinicians.
Abbott Northwestern Hospital in Minneapolis, Min-
esota, has developed a similar STEMI transfer protocol
nd has reported their initial experiences. By use of this
ntegrated transfer system, 57 patients from eight hospitals
ere rapidly and safely transferred for primary PCI with the
ean time from initial hospital arrival to first balloon
nflation of 98 min (29).
TANDARDIZING THE EVALUATION
F TRANSFER STRATEGIES FOR PRIMARY PCI
s transfer approaches are adopted in the U.S., standard
erminology is needed to designate common time intervals
nd outcome variables for evaluating transfer strategies.
nalysis of the four large randomized trials comparing
n-site fibrinolysis with transfer for primary PCI revealed
ariable definitions and inconsistent reporting of critical
reatment time intervals, making it difficult to interpret and
ompare results (Table 1) (9–12). Disparities also are
vident in the Centers for Medicare and Medicaid Services
003 report of mean “door-to-balloon” time of 356 min for
90 participating U.S. hospitals (30). The accuracy of the
enters for Medicare and Medicaid Services data is uncer-
ain but points to the difficulties in accurately identifying
atients with STEMI who are eligible for reperfusion with
rimary PCI, data collection, and studying quality measures
n patients undergoing primary PCI.
We propose the following standard time intervals and
erminology for evaluating transfer strategies for primary
CI: 1) time at referral hospital time from initial hospital
rrival until transfer to PCI hospital; 2) transfer time time
rom transfer from referral hospital until arrival at PCI
ospital; 3) door-to-balloon time  time from arrival at
CI hospital until first balloon inflation; 4) first medical
ontact to first balloon inflation at PCI hospital total time
rom first contact by medical personnel to reperfusion with
CI; and 5) symptom onset to first balloon inflation at PCI
ospital total time from onset of symptoms to reperfusion
ith PCI. Such standardization of critical time intervals will
elp guide the ongoing assessment of transfer strategies for
rimary PCI in clinical practice and results from prospective
linical trials.
ONCLUSIONS
s the reperfusion era continues to evolve, the focus of
TEMI care must change from subtle refinements in care to
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Establishing Transfer Protocols for STEMI Patients June 16, 2004:2153–9idespread changes in health care systems. Patient access to
apid, high-quality primary PCI should increase, and ded-
cated transfer strategies offer the greatest potential to
ccomplish this goal. Multiple studies have documented the
otential for improved outcomes with a strategy of transfer
or primary PCI compared with the administration of
brinolytic therapy at community hospitals; however, a
efinitive, large-scale clinical trial is needed to verify the
esults of these small studies in the U.S. Potent pharmaco-
ogic “transfer regimens” hold promise for improving early
eperfusion of the infarct vessel before primary PCI, so these
egimens should also be tested further in prospective clinical
rials evaluating transfer strategies. However, poor enroll-
ent leading to early termination of the AIR-PAMI and
tlantic Cardiovascular Patient Outcomes Research Team
rials suggests that U.S. investigators are unwilling to
andomize STEMI patients in trials evaluating new ap-
roaches for STEMI care (8,12). Acute STEMI networks
ill be needed to improve participation in clinical trials in
he U.S., delineate the optimal approach to STEMI care,
vercome obstacles that may hinder further study of transfer
trategies, and extend the benefits of mechanical reperfusion
o more patients with STEMI. (30)
eprint requests and correspondence: Dr. Matthew T. Roe,
400 Pratt Street, Durham, North Carolina 27705. E-mail:
oe00001@mc.duke.edu.
EFERENCES
1. PCAT Collaborators. Primary coronary angioplasty compared with
intravenous thrombolytic therapy for acute myocardial infarction:
six-month follow up and analysis of individual patient data from
randomized trials. Am Heart J 2003;145:47–57.
2. Topol EJ, Kereiakes DJ. Regionalization of care for acute ischemic
heart disease: a call for specialized centers. Circulation 2003;107:
1463–6.
3. MacKenzie EJ, Hoyt DB, Sacra JC, et al. National inventory of
hospital trauma centers. JAMA 2003;289:1515–22.
4. Nathens AB, Jurkovich GJ, Cummings P, Rivar FP, Maier RV. The
effect of organized systems of trauma care on motor vehicle crash
mortality. JAMA 2000;283:1990–4.
5. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intra-
venous thrombolytic therapy for acute myocardial infarction: a quan-
Table 1. Median Time Intervals for Patients R
Percutaneous Coronary Intervention
Study (Ref.)
Door to
Randomization
(min)
Rand
to D
(
PRAGUE-1 (10)
(n  101)
15
PRAGUE-2 (11)
(n  429)
20
DANAMI-2 (9)
(n  567)
22
AIR-PAMI (12)
(n  71)
35
*Time from arrival at tertiary hospital until first balloon infl
NR  not reported.titative review of 23 randomised trials. Lancet 2003;361:13–20.6. Rogers WJ, Canto JG, Barron HV, Boscarino JA, Shoultz DA, Every
NR. Treatment and outcome of myocardial infarction in hospitals with
and without invasive capability. J Am Coll Cardiol 2000;35:371–9.
7. Smith SC Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines for
percutaneous coronary intervention (revision of the 1993 PTCA
guidelines): a report of the American College of Cardiology/American
Heart Association task force on practice guidelines (committee to
revise the 1993 guidelines for percutaneous transluminal coronary
angioplasty). J Am Coll Cardiol 2001;37:2215–39.
8. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy
vs. primary percutaneous coronary intervention for myocardial infarc-
tion in patients presenting to hospitals without onsite cardiac surgery.
JAMA 2002;287:1943–51.
9. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of
coronary angioplasty with fibrinolytic therapy in acute myocardial
infarction. N Engl J Med 2003;349:733–42.
0. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F,
Suryapranata H. Multicentre randomized trial comparing transport to
primary angioplasty vs immediate thrombolysis vs combined strategy
for patients with acute myocardial infarction presenting to a commu-
nity hospital without a catheterization laboratory. Eur Heart J 2000;
21:823–31.
1. Widimsky P, Budesinsky T, Vorac D, et al., for the PRAGUE Study
Group Investigators. Long distance transport for primary angioplasty
vs. immediate thrombolysis in acute myocardial infarction. Final
results of the randomized national multicentre trial—PRAGUE-2.
Eur Heart J 2003;24:94–104.
2. Grines CL, Westerhausen DR Jr, Grines LL, et al. A randomized trial
of transfer for primary angioplasty versus onsite thrombolysis in
patients with high-risk myocardial infarction: the Air Primary Angio-
plasty in Myocardial Infarction study. J Am Coll Cardiol 2002;39:
1713–9.
3. Vermeer F, Oude Ophuis AJM, vd Berg EJ, et al. Prospective
randomised comparison between thrombolysis, rescue PTCA, and
primary PTCA in patients with extensive myocardial infarction ad-
mitted to a hospital without PTCA facilities: a safety and feasibility
study. Heart 1999;82:426–31.
4. Zijlstra F. Angioplasty vs. thrombolysis for acute myocardial infarc-
tion: a quantitative overview of the effects of interhospital transporta-
tion. Eur Heart J 2003;24:21–3.
5. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for
primary angioplasty versus immediate thrombolysis in acute myocar-
dial infarction: a meta-analysis. Circulation 2003;108:1809–14.
6. Fibrinolytic Therapy Trialists’ Collaborative Group. Indications for
fibrinolytic therapy in suspected acute myocardial infarction: collabo-
rative overview of early mortality and major morbidity results from all
randomised trials of more than 1,000 patients. Lancet 1994;343:
311–22.
7. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of
symptom-onset-to-balloon time and door-to-balloon time with mor-
tality in patients undergoing angioplasty for acute myocardial infarc-
tion. JAMA 2000;283:2941–7.
8. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute
mly Assigned to Transfer for Primary
tion
ure
Transfer
Time
(min)
Door to
Balloon*
(min)
Symptom
Onset to
Balloon
(min)
35 28 215
48 26 277
32 26 224
26 25 NR
uring percutaneous coronary intervention.ando
omiza
epart
min)
17
NR
38
38
ation dmyocardial infarction in patients presenting with ST-segment eleva-
12
2
2
2
2
2
2
2
2
2
3
2159JACC Vol. 43, No. 12, 2004 Waters et al.
June 16, 2004:2153–9 Establishing Transfer Protocols for STEMI Patientstion. The Task Force on the Management of Acute Myocardial
Infarction of the European Society of Cardiology. Eur Heart J
2003;1:28–66.
9. Groch L, Horncek I, Hlinomaz O, et al. The 4-year clinical and
angiographic follow-up in patients with acute myocardial infarction
treated with immediate thrombolysis versus primary angioplasty versus
combined strategy: single-center randomized trial, subgroup of
PRAGUE study (abstr). Am J Cardiol 2003;92 Suppl 6A:152L.
0. Montalescot G, Barragan P, Wittenberg O, et al. Abciximab before
direct angioplasty and stenting in myocardial infarction regarding
acute and long term follow-up. N Engl J Med 2001;344:1895–903.
1. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion
strategy for acute myocardial infarction. J Am Coll Cardiol 2003;42:
1886–9.
2. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of
early percutaneous coronary intervention after reteplase with or
without abciximab in acute myocardial infarction: results from the
SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol 2000;36:
1489 –96.
3. Antman EM, Giugliano RP, Gibson CM, et al., for the TIMI 14
Investigators. Abciximab facilitates the rate and extent of thromboly-
sis: result of the Thrombolysis In Myocardial Infarction (TIMI) 14
Trial. Circulation 1999;99:2720–32.
4. Giugliano RP, Roe MT, Harrington RA, et al. Combination reper-
fusion therapy with eptifibatide and reduced-dose tenecteplase forST-elevation myocardial infarction: results of integrilin and tenect-
eplase in acute myocardial infarction (INTEGRITI) phase II angiog-
raphy trial. J Am Coll Cardiol 2003;41:1251–60.
5. Henriques JP, Haassdijk AP, Zijlstra F. Outcome of primary angio-
plasty for acute myocardial infarction during routine duty hours versus
during off-hours. J Am Coll Cardiol 2003;41:2138–42.
6. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment
on mortality after prehospital fibrinolysis or primary angioplasty. Data
from the CAPTIM randomized clinical trial. Circulation 2003;108:
2851–6.
7. Canto JG, Every NR, Magid DJ, et al. The volume of primary
angioplasty procedures and survival after acute myocardial infarction.
N Engl J Med 2000;342:1573–80.
8. Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital
primary angioplasty volume and mortality for patients with acute MI
treated with primary angioplasty vs. thrombolytic therapy. JAMA
2000;284:3131–8.
9. Larson DM, Sharkey SW, Unger BT, et al. Is rapid transfer of
ST-elevation myocardial infarction patients for primary angioplasty
feasible in the United States? (abstr). Am J Cardiol 2003;92 Suppl
6A:152L.
0. Joint Commission on Accreditation of Healthcare Organizations’
ORYX Acute Myocardial Infarction Core Measure Set. Available at:
http://www.jcaho.org/. Accessed March 29, 2004.
